Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.

Britain's pharmacy regulator warned it had been forced to step in, to 'investigate concerns' that prescription drugs had been ...

A weight loss pill called orforglipron has had some successful results from the human trial stage, so when could we see it on the NHS?

AN influencer says she’s been trolled for still eating her favourite pizza, smothered in chips, cheese and curry sauce.

A trial of 3,127 patients who took a daily pill for 72 weeks saw an average weight loss per person of 12.3kg. While injectable obesity drugs are peptides designed to replicate the appetite-controlling ...

Lisa Bernett lost more than 10 stone without jabs or surgery. She shares how she transformed her eating habits and fitness ...

Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity injections like its Zepbound offering or Novo’s Wegovy. Both of the ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...